A 16-amino-acid peptide versus a small-molecule NNMT inhibitor. How MOTS-c and 5-amino-1MQ differ in chemistry, target, research models and evidence.
By the MOTS-C Peptide editorial team·Last reviewed ·Sources: editorially approved
Short answer
These are different kinds of molecule attacking metabolism from different directions. 5-amino-1MQ is a small synthetic compound of 159 g/mol developed to inhibit a named enzyme, NNMT [PubChem][Neelakantan 2018]. MOTS-c is a 16-amino-acid peptide more than thirteen times its weight, with no identified target [FDA 2026]. What they share is a mouse obesity literature and a marketing category.
MOTS-c and 5-amino-1MQ compared field by field. Each column describes that substance only; the rows are not scores.
MOTS-c
5-amino-1MQ
Kind of molecule
A peptide, 16 amino acids
A small molecule; a quaternary ammonium cation
Molecular formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
C₁₀H₁₁N₂⁺
Molecular weight
2174.6 g/mol
159.21 g/mol
Where it comes from
Encoded in mitochondrial DNA (MT-RNR1)
Synthetic; a methylated quinoline derivative
Target
Unidentified
Nicotinamide N-methyltransferase (NNMT), a named enzyme
Most-cited evidence
Mouse and cell work on insulin sensitivity and diet-induced obesity
Mouse work on diet-induced obesity with NNMT inhibitors
Randomised human trials published
None
None
Approval status
Not approved; FDA staff recommended against compounding listing in 2026
Not an approved medicine
Prohibited in sport
Yes, at all times (WADA S4)
Not listed by name
A designed inhibitor versus a discovered peptide
The two came about in opposite ways, which explains most of the differences in the table.
5-amino-1MQ was made. NNMT was identified as a candidate target in obesity, and small-molecule inhibitors were developed against it and tested in diet-induced obese mice [Neelakantan 2018]. The compound exists because the target came first, which is why its mechanism can be stated in one line.
MOTS-c was found. It emerged from a search of mitochondrial rRNA genes for hidden coding sequences, and its effects were characterised afterwards [Lee et al. 2015]. The mechanism is still a proposed chain rather than a binding interaction, and FDA noted in 2026 that its molecular targets remain unknown [FDA 2026].
Why the pairing exists at all
Both are sold into the same market and promoted for similar outcomes, which is enough to generate the search. The biological link is thin: NNMT acts on nicotinamide, which sits in NAD+ metabolism, and MOTS-c has been linked to AMPK, which responds to cellular energy state. Both therefore touch “metabolism” at some remove, but nothing in the indexed literature connects them.
Of the 253 MOTS-c publications indexed here, none mentions 5-amino-1MQ or NNMT. That absence is the most reliable thing this page can tell you.
Size matters for how they behave
At 159 g/mol, 5-amino-1MQ is a small molecule of the kind that can often be absorbed orally. At 2174.6 g/mol, MOTS-c is a peptide [PubChem], and peptides of that size are generally poorly absorbed by mouth and vulnerable to digestion. That difference shapes how each has been studied, and it is one reason results in one cannot be used to reason about the other.
For MOTS-c specifically, FDA also raised immunogenicity: a 16-residue peptide given by injection can provoke an immune response, and the agency could not rule it out given the absence of impurity and aggregate data [FDA 2026]. A small molecule does not carry that particular risk.
Where each one stands
Neither is approved. MOTS-c additionally sits on the WADA Prohibited List at all times [WADA 2026], and one Phase 2a trial of administered MOTS-c in prediabetes is recruiting [NCT07505745]. See the MOTS-c metabolic research for what has actually been reported, and MOTS-c vs NAD+ for the adjacent comparison.
Frequently asked questions
What is the difference between MOTS-c and 5-amino-1MQ?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. 5-amino-1MQ is a small synthetic molecule, a quaternary ammonium cation of 159 g/mol, developed as an inhibitor of the enzyme nicotinamide N-methyltransferase. One is a peptide with no identified target; the other is a small molecule designed against a named enzyme.
Which one has human evidence?
Neither. The 5-amino-1MQ work most often cited is a mouse study of diet-induced obesity. No published randomised trial has given either compound to people and reported outcomes.
Has any study compared them?
Not in this index. None of the indexed MOTS-c publications mentions 5-amino-1MQ or NNMT. Comparisons in circulation are inference from separate mouse experiments.
Do they work the same way?
No. 5-amino-1MQ is described as inhibiting NNMT, a specific enzyme. MOTS-c has been linked to folate-cycle inhibition and AMPK activation in cells, but its direct molecular target is unknown.
Is 5-amino-1MQ approved?
No. Neither compound is an approved medicine, and neither has an established human dose.
References
Lee C, Zeng J, Drew BG et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. PubMed 25738459 · doi:10.1016/j.cmet.2015.02.009 · Study record[Animal, tier C]
National Center for Biotechnology Information. PubChem Compound CID 146675088: Mots-c. Source[retrieved 2026-11-11]
National Center for Biotechnology Information. PubChem Compound CID 950107: 5-Amino-1-methylquinolinium. Source[retrieved 2026-11-11]
Neelakantan H et al., Biochem Pharmacol (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Source[retrieved 2026-11-11]
U.S. Food and Drug Administration (2026-05-11). FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate). Source[retrieved 2026-11-11]
ClinicalTrials.gov (2026-04-01). MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). Source[retrieved 2026-11-11]
World Anti-Doping Agency (2026-01-01). The Prohibited List (S4 Hormone and Metabolic Modulators: activators of AMP-activated protein kinase). Source[retrieved 2026-11-11]